Roy Joey, Carrier Serge
McGill University, Montreal, Canada.
J Sex Med. 2008 Dec;5(12):2967-9. doi: 10.1111/j.1743-6109.2008.00918.x. Epub 2008 Jul 1.
Potassium para-aminobenzoate is an agent used in the treatment of sclerotic diseases including Peyronie's disease of the penis. It has been reported that this medication may have been responsible for cases of acute liver injury.
To inform clinicians of the possibility of an adverse drug event associated with the oral intake of potassium para-aminobenzoate by reporting an additional case and compiling information from previous reports.
The affected patient's medical records were diligently reviewed; all available and relevant information pertaining to this adverse event is reported. Similar case reports were analyzed and compared, and relevant information was compiled in this report.
The patient enjoyed a full biochemical recovery from his hepatitis 4 months after discontinuation of potassium para-aminobenzoate.
To date, the oral use of potassium para-aminobenzoate has been reported to be linked to acute liver injury in six individuals. Appropriate management of this adverse drug event is the immediate discontinuation of the offending drug and general patient support measures.
对氨基苯甲酸钾是一种用于治疗包括阴茎佩罗尼氏病在内的硬化性疾病的药物。据报道，这种药物可能是导致急性肝损伤病例的原因。
通过报告另一例病例并汇总先前报告中的信息，告知临床医生口服对氨基苯甲酸钾可能引发药物不良事件。
认真查阅了受影响患者的病历；报告了与该不良事件相关的所有可用信息。对类似病例报告进行了分析和比较，并在本报告中汇总了相关信息。
患者在停用对氨基苯甲酸钾4个月后，肝炎实现了完全生化恢复。
迄今为止，已有报道称6人因口服对氨基苯甲酸钾而导致急性肝损伤。对这种药物不良事件的适当处理是立即停用致病药物并采取一般的患者支持措施。
